Atlas Trials

Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine

Clinical trial NCT00562237 · TERMINATED

Trial details

NCT number
NCT00562237
Sponsor
Solvay Pharmaceuticals
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy Subjects
Start date
2007-07-01
Primary completion
2007-11-01
Enrollment
400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.